Cargando…

Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice

AIM: Immunotherapies blocking the CD47‐SIRPα pathway by targeting CD47 enhance macrophage phagocytosis of neoplastic cells in mouse models. As SIRPα exhibits relatively restricted tissue expression, SIRPα antagonists may be better tolerated than agents targeting CD47, which is ubiquitously expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Tomoyuki, Tanaka, Yuka, Piao, Jinlian, Tanimine, Naoki, Oue, Naohide, Hinoi, Takao, Garcia, Noel Verjan, Miyasaka, Masayuki, Matozaki, Takashi, Yasui, Wataru, Ohdan, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236110/
https://www.ncbi.nlm.nih.gov/pubmed/30460349
http://dx.doi.org/10.1002/ags3.12205
_version_ 1783370974626840576
author Abe, Tomoyuki
Tanaka, Yuka
Piao, Jinlian
Tanimine, Naoki
Oue, Naohide
Hinoi, Takao
Garcia, Noel Verjan
Miyasaka, Masayuki
Matozaki, Takashi
Yasui, Wataru
Ohdan, Hideki
author_facet Abe, Tomoyuki
Tanaka, Yuka
Piao, Jinlian
Tanimine, Naoki
Oue, Naohide
Hinoi, Takao
Garcia, Noel Verjan
Miyasaka, Masayuki
Matozaki, Takashi
Yasui, Wataru
Ohdan, Hideki
author_sort Abe, Tomoyuki
collection PubMed
description AIM: Immunotherapies blocking the CD47‐SIRPα pathway by targeting CD47 enhance macrophage phagocytosis of neoplastic cells in mouse models. As SIRPα exhibits relatively restricted tissue expression, SIRPα antagonists may be better tolerated than agents targeting CD47, which is ubiquitously expressed in many tissues. Here, we investigated the therapeutic impact of monoclonal antibodies (mAbs) against CD47 and/or SIRPα on gastroenterological tumors in syngeneic immunocompetent mouse models. METHODS: We used in vitro and in vivo phagocytosis assays in C57BL/6J (B6) mice to investigate anti‐CD47/SIRPα mAb effects on Hepa1‐6 and CMT93 originating from B6 mice. The influence of these mAbs on macrophage transmigration was also assessed. To investigate anti‐SIRPα mAb therapy‐induced inhibitory effects on sporadic colon cancer growth, we used a CDX2P9.5‐NLS Cre;APC (+) /FLOX (CPC‐APC) mouse model. RESULTS: Systemic anti‐SIRPα mAb administration significantly increased Hepa1‐6 and CMT93 cell susceptibility to macrophage phagocytosis, both in vitro and in vivo. Conversely, similarly administered anti‐CD47 mAb did not promote macrophage phagocytosis of target cells, whereas cells incubated with anti‐CD47 mAb prior to inoculation were more susceptible to macrophage phagocytosis. In vitro cell migration assays revealed that binding with anti‐CD47 mAb inhibited macrophage transmigration. Anti‐SIRPα mAb treatment inhibited tumor progression in CPC‐APC mice and significantly improved overall survival. Anti‐CD47 mAb administration in vivo eliminated the phagocytosis‐promoting CD47 blockade effect, probably by inhibiting macrophage transmigration/chemotaxis. In contrast, anti‐SIRPα mAb exhibited enhanced macrophage phagocytic activity and marked anti‐tumor effects against gastroenterological malignancies. CONCLUSION: SIRPα mAb augmentation of macrophage phagocytic activity may represent an effective treatment strategy for human gastrointestinal tumors.
format Online
Article
Text
id pubmed-6236110
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62361102018-11-20 Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice Abe, Tomoyuki Tanaka, Yuka Piao, Jinlian Tanimine, Naoki Oue, Naohide Hinoi, Takao Garcia, Noel Verjan Miyasaka, Masayuki Matozaki, Takashi Yasui, Wataru Ohdan, Hideki Ann Gastroenterol Surg Original Articles AIM: Immunotherapies blocking the CD47‐SIRPα pathway by targeting CD47 enhance macrophage phagocytosis of neoplastic cells in mouse models. As SIRPα exhibits relatively restricted tissue expression, SIRPα antagonists may be better tolerated than agents targeting CD47, which is ubiquitously expressed in many tissues. Here, we investigated the therapeutic impact of monoclonal antibodies (mAbs) against CD47 and/or SIRPα on gastroenterological tumors in syngeneic immunocompetent mouse models. METHODS: We used in vitro and in vivo phagocytosis assays in C57BL/6J (B6) mice to investigate anti‐CD47/SIRPα mAb effects on Hepa1‐6 and CMT93 originating from B6 mice. The influence of these mAbs on macrophage transmigration was also assessed. To investigate anti‐SIRPα mAb therapy‐induced inhibitory effects on sporadic colon cancer growth, we used a CDX2P9.5‐NLS Cre;APC (+) /FLOX (CPC‐APC) mouse model. RESULTS: Systemic anti‐SIRPα mAb administration significantly increased Hepa1‐6 and CMT93 cell susceptibility to macrophage phagocytosis, both in vitro and in vivo. Conversely, similarly administered anti‐CD47 mAb did not promote macrophage phagocytosis of target cells, whereas cells incubated with anti‐CD47 mAb prior to inoculation were more susceptible to macrophage phagocytosis. In vitro cell migration assays revealed that binding with anti‐CD47 mAb inhibited macrophage transmigration. Anti‐SIRPα mAb treatment inhibited tumor progression in CPC‐APC mice and significantly improved overall survival. Anti‐CD47 mAb administration in vivo eliminated the phagocytosis‐promoting CD47 blockade effect, probably by inhibiting macrophage transmigration/chemotaxis. In contrast, anti‐SIRPα mAb exhibited enhanced macrophage phagocytic activity and marked anti‐tumor effects against gastroenterological malignancies. CONCLUSION: SIRPα mAb augmentation of macrophage phagocytic activity may represent an effective treatment strategy for human gastrointestinal tumors. John Wiley and Sons Inc. 2018-09-10 /pmc/articles/PMC6236110/ /pubmed/30460349 http://dx.doi.org/10.1002/ags3.12205 Text en © 2018 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Abe, Tomoyuki
Tanaka, Yuka
Piao, Jinlian
Tanimine, Naoki
Oue, Naohide
Hinoi, Takao
Garcia, Noel Verjan
Miyasaka, Masayuki
Matozaki, Takashi
Yasui, Wataru
Ohdan, Hideki
Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title_full Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title_fullStr Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title_full_unstemmed Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title_short Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
title_sort signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236110/
https://www.ncbi.nlm.nih.gov/pubmed/30460349
http://dx.doi.org/10.1002/ags3.12205
work_keys_str_mv AT abetomoyuki signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT tanakayuka signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT piaojinlian signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT taniminenaoki signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT ouenaohide signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT hinoitakao signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT garcianoelverjan signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT miyasakamasayuki signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT matozakitakashi signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT yasuiwataru signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice
AT ohdanhideki signalregulatoryproteinalphablockadepotentiatestumoricidaleffectsofmacrophagesongastroenterologicalneoplasticcellsinsyngeneicimmunocompetentmice